K J Hoffmann

426 total citations
20 papers, 367 citations indexed

About

K J Hoffmann is a scholar working on Pharmacology, Oncology and Molecular Biology. According to data from OpenAlex, K J Hoffmann has authored 20 papers receiving a total of 367 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pharmacology, 8 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in K J Hoffmann's work include Pharmacogenetics and Drug Metabolism (13 papers), Drug Transport and Resistance Mechanisms (8 papers) and Drug-Induced Hepatotoxicity and Protection (5 papers). K J Hoffmann is often cited by papers focused on Pharmacogenetics and Drug Metabolism (13 papers), Drug Transport and Resistance Mechanisms (8 papers) and Drug-Induced Hepatotoxicity and Protection (5 papers). K J Hoffmann collaborates with scholars based in Sweden. K J Hoffmann's co-authors include Lars Weidolf, K. O. Borg, Lars Renberg, Inger Skånberg, C G Regårdh, Per Lundborg, L. Andersson, Ola Rönn, B. Edgar and Christer Tannergren and has published in prestigious journals such as Drugs, Drug Metabolism and Disposition and European Journal of Clinical Pharmacology.

In The Last Decade

K J Hoffmann

20 papers receiving 299 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K J Hoffmann Sweden 14 178 101 84 75 64 20 367
P O Lagerström Sweden 9 101 0.6× 67 0.7× 69 0.8× 68 0.9× 43 0.7× 14 428
Tamara A. Sutfin United States 11 142 0.8× 100 1.0× 50 0.6× 145 1.9× 71 1.1× 13 728
G. Ahr Germany 12 123 0.7× 96 1.0× 143 1.7× 57 0.8× 108 1.7× 22 571
Gregory M. Kochak Switzerland 12 89 0.5× 77 0.8× 55 0.7× 60 0.8× 105 1.6× 34 483
Y. Shiobara United Kingdom 11 93 0.5× 84 0.8× 59 0.7× 102 1.4× 37 0.6× 22 409
William Schary United States 10 220 1.2× 89 0.9× 49 0.6× 117 1.6× 48 0.8× 26 623
H.F. Woods United Kingdom 8 328 1.8× 130 1.3× 105 1.3× 102 1.4× 59 0.9× 9 708
Gohachiro Miyamoto Japan 12 140 0.8× 122 1.2× 45 0.5× 128 1.7× 61 1.0× 35 485
T. W. Guentert Switzerland 15 157 0.9× 95 0.9× 46 0.5× 233 3.1× 53 0.8× 28 517
DD Breimer Netherlands 15 270 1.5× 123 1.2× 87 1.0× 89 1.2× 147 2.3× 21 689

Countries citing papers authored by K J Hoffmann

Since Specialization
Citations

This map shows the geographic impact of K J Hoffmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K J Hoffmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K J Hoffmann more than expected).

Fields of papers citing papers by K J Hoffmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K J Hoffmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K J Hoffmann. The network helps show where K J Hoffmann may publish in the future.

Co-authorship network of co-authors of K J Hoffmann

This figure shows the co-authorship network connecting the top 25 collaborators of K J Hoffmann. A scholar is included among the top collaborators of K J Hoffmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K J Hoffmann. K J Hoffmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tannergren, Christer, Peter Langguth, & K J Hoffmann. (2001). Compound mixtures in Caco-2 cell permeability screens as a means to increase screening capacity.. PubMed. 56(4). 337–42. 17 indexed citations
2.
Lennernäs, Hans, Lars Renberg, K J Hoffmann, & C G Regårdh. (1993). Presystemic elimination of the beta-blocker pafenolol in the rat after oral and intraperitoneal administration and identification of a main metabolite in both rats and humans.. Drug Metabolism and Disposition. 21(3). 435–440. 7 indexed citations
3.
Eriksson, Ulf G., et al.. (1991). Pharmacokinetics of the enantiomers of felodipine in the dog after oral and intravenous administration of a pseudoracemic mixture. Xenobiotica. 21(1). 75–84. 14 indexed citations
4.
Renberg, Lars, et al.. (1989). Identification of two main urinary metabolites of [14C]omeprazole in humans.. Drug Metabolism and Disposition. 17(1). 69–76. 44 indexed citations
5.
Hoffmann, K J & L. Andersson. (1987). Metabolism of [14C] Felodipine, a New Vasodilating Drug, in Healthy Volunteers. Drugs. 34(Supplement 3). 43–52. 17 indexed citations
6.
Hoffmann, K J, et al.. (1986). Comparative metabolic disposition of oral doses of omeprazole in the dog, rat, and mouse.. Drug Metabolism and Disposition. 14(3). 336–340. 12 indexed citations
7.
Hoffmann, K J. (1986). Identification of the main urinary metabolites of omeprazole after an oral dose to rats and dogs.. Drug Metabolism and Disposition. 14(3). 341–348. 20 indexed citations
8.
Bäckman, Assar, et al.. (1986). Biotransformation of felodipine in liver microsomes from rat, dog, and man.. Drug Metabolism and Disposition. 14(5). 613–618. 22 indexed citations
9.
Hoffmann, K J & Lars Weidolf. (1985). Identification of felodipine metabolites in rat urine. Journal of Mass Spectrometry. 12(8). 414–423. 19 indexed citations
10.
Edgar, B., K J Hoffmann, Per Lundborg, et al.. (1985). Absorption, Distribution and Elimination of Felodipine in Man. Drugs. 29(Supplement 2). 9–15. 42 indexed citations
11.
Hoffmann, K J, et al.. (1984). Stereoselective disposition of RS-tocainide in man. European Journal of Drug Metabolism and Pharmacokinetics. 9(3). 215–222. 17 indexed citations
12.
Weidolf, Lars, K. O. Borg, & K J Hoffmann. (1984). Urinary metabolites of felodipine, a new vasodilator drug, in man, dog, rat and mouse. Xenobiotica. 14(8). 657–666. 41 indexed citations
13.
Graffner, Christina, et al.. (1983). Pharmacokinetics of prenalterol after single and multiple administration of controlled release tablets to patients with congestive heart failure. European Journal of Clinical Pharmacology. 24(4). 495–502. 7 indexed citations
14.
Hoffmann, K J, et al.. (1982). The metabolic disposition of the selective beta 1-adrenoceptor agonist prenalterol in mice, rats, dogs, and humans.. Drug Metabolism and Disposition. 10(2). 173–179. 15 indexed citations
15.
Graffner, Christina, et al.. (1981). Pharmacokinetic studies in man of the selective beta1-adrenoceptor agonist, prenalterol. European Journal of Clinical Pharmacology. 20(2). 91–97. 13 indexed citations
16.
Hoffmann, K J, Inger Skånberg, & K. O. Borg. (1979). Biotransformation of Alprenolol in Dog, Guinea-pig and Rat Liver Microsomes. Xenobiotica. 9(2). 79–91. 7 indexed citations
17.
Hoffmann, K J, et al.. (1979). Identification of Urinary and Biliary Metabolites of Alprenolol in the Rat. Xenobiotica. 9(2). 93–106. 13 indexed citations
18.
Hoffmann, K J, Inger Skånberg, & K. O. Borg. (1979). Species differences in the metabolism of pamatolol, a cardioselective beta — adrenoceptor antagonist. European Journal of Drug Metabolism and Pharmacokinetics. 4(3). 163–173. 2 indexed citations
19.
Borg, K. O., et al.. (1976). Metabolism of Metoprolol in the Ratin vitroandin vivo. Xenobiotica. 6(11). 691–711. 37 indexed citations
20.
Hoffmann, K J, et al.. (1969). [Effect of steroids and irradiation on the incorporation of 14C-thymidine, 14C-uridine and 14C-leucine in Ehrlich ascites carcinoma of mice in vitro].. PubMed. 138(4). 471–80. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by P O Lagerström Breakdown of academic impact, for papers by Tamara A. Sutfin Breakdown of academic impact, for papers by G. Ahr Breakdown of academic impact, for papers by Gregory M. Kochak Breakdown of academic impact, for papers by Y. Shiobara Breakdown of academic impact, for papers by William Schary Breakdown of academic impact, for papers by H.F. Woods Breakdown of academic impact, for papers by Gohachiro Miyamoto Breakdown of academic impact, for papers by T. W. Guentert Breakdown of academic impact, for papers by DD Breimer
Rankless by CCL
2026